DNMT1介导的BEX1甲基化调控肝癌干性与致瘤性
该研究在5种小鼠HCC模型中分析干性评分,并从HCC细胞系分选BEX1阳性与阴性细胞进行转录组分析,发现BEX1是新CSC标志物且为肝CSC自我更新所必需。DNMT1抑制剂zebularine可去除表观抑制重新激活BEX1。BEX1在HB和CSC-HCC患者中高表达,在非CSC-HCC中不表达,DNMT1介导的BEX1启动子甲基化导致三种患者中BEX1表达差异。机制上BEX1与RUNX3互作阻断其对β-catenin转录的抑制,激活Wnt/β-catenin信号维持干性。
要点
- BEX1是新肝癌干细胞标志物,为肝CSC自我更新所必需
- DNMT1抑制剂zebularine可去除表观抑制重新激活BEX1
- BEX1通过阻断RUNX3对β-catenin的抑制激活Wnt/β-catenin维持干性
核心结论
- BEX1受DNMT1调控,通过激活Wnt/β-catenin信号维持肝CSC自我更新,是HB和CSC-HCC的潜在治疗靶点。
研究设计与样本
- 在5种小鼠HCC模型中分析干性评分。
- 从HCC细胞系分选BEX1阳性与阴性细胞亚群进行转录组分析。
- 通过western blotting、成球实验和异种移植肿瘤模型检测BEX1表达与功能。
主要发现
- BEX1是新CSC标志物,为肝CSC自我更新所必需。
- zebularine可去除表观抑制重新激活BEX1。
- BEX1在HB和CSC-HCC患者中高表达,在非CSC-HCC患者中不表达。
- DNMT1介导的BEX1启动子甲基化导致HB、CSC-HCC和非CSC-HCC患者中BEX1表达差异。
- BEX1与RUNX3互作阻断其对β-catenin转录的抑制,激活Wnt/β-catenin信号维持干性。
临床怎么用
- BEX1可作为HB和CSC-HCC的潜在治疗靶点。
- 靶向BEX1介导的Wnt/β-catenin信号可能有助于应对肝癌高复发率和异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Hepatoblastoma (HB) and hepatocellular carcinoma (HCC) both exhibit notable cancer stem cell (CSC) features. Moreover, the development of both diseases is closely associated with the presence of CSCs. We investigated the role of brain-expressed X-linked protein 1 (BEX1) in regulating the CSC properties of HB and a subtype of HCC with high CSC features (CSC-HCC). METHODS: Stemness scores were analyzed in 5 murine HCC models. A subpopulation of BEX1-positive cells and BEX1-negative cells were sorted from HCC cell lines, and subjected to transcriptome analysis. The expression and function of BEX1 was examined via western blotting, sphere formation assays, and xenograft tumor models. RESULTS: We identified BEX1 as a novel CSC marker that was required for the self-renewal of liver CSCs. Furthermore, zebularine, a potent DNMT1 inhibitor, can induce the reactivation of BEX1 by removing epigenetic inhibition. Notably, BEX1 was highly expressed in patients with HB and CSC-HCC, but not in patients with non-CSC HCC. Moreover, DNMT1-mediated methylation of the BEX1 promoter resulted in differential BEX1 expression patterns in patients with HB, CSC-HCC, and non-CSC-HCC. Mechanistically, BEX1 interacted with RUNX3 to block its inhibition of β-catenin transcription, which led to the activation of Wnt/β-catenin signaling, and stemness maintenance in both HB and CSC-HCC. In contrast, downregulated BEX1 expression released RUNX3 and inhibited the activation of Wnt/β-catenin signaling in non-CSC-HCC. CONCLUSION: BEX1, under the regulation of DNMT1, is necessary for the self-renewal and maintenance of liver CSCs through activation of Wnt/β-catenin signaling, rendering BEX1 a potentially valuable therapeutic target in both HB and CSC-HCC. LAY SUMMARY: Cancer stem cells (CSCs) contribute to a high rate of cancer recurrence, as well as resistance to conventional therapies. However, the regulatory mechanisms underlying their self-renewal remains elusive. Herein, we have reported that BEX1 plays a key role in regulating CSC properties in different types of liver cancer. Targeting BEX1-mediated Wnt/β-catenin signaling may help to address the high rate of recurrence, and heterogeneity of liver cancer.
引用
- Wang Q, Liang N, Yang T, et al. DNMT1-mediated methylation of BEX1 regulates stemness and tumorigenicity in liver cancer. J Hepatol. 2021. PMID: 34217777. doi:10.1016/j.jhep.2021.06.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。